News
🇺🇸 AmericasLatest pharmaceutical news, drug approvals, and FDA regulatory updates
Latest News
Clinical Outsourcing Trends 2026: Key Focus Areas
Clinical outsourcing in 2026 is being reshaped by AI, real-world data, and eSource systems, addressing key challenges in trial efficiency and data management. Predictive analytics and data-driven strategies are becoming essential for optimizing clinical trial processes.
Unveiling the 4th Annual COG: What to Expect (If It Exists)
NovaPharmaNews was unable to verify the existence of a 4th Annual COG conference through pharmaceutical event databases or authoritative sources. Publication of this article cannot proceed without confirmed event details.
Pharma Compliance Congress 2026: Enforcement Trends & DOJ Insights
The Pharmaceutical Compliance Congress (PCC) 2026 focuses on enforcement trends, best practices, and networking for compliance, regulatory, and legal professionals. Key themes include heightened FDA enforcement, supply chain oversight, and promotional compliance.
AACR 2026: Pembrolizumab Bowel Cancer Success, Moderna Melanoma Data
Key updates from AACR 2026 include pembrolizumab (Keytruda) showing zero relapses in bowel cancer, Moderna's melanoma data, and Revolution Medicines' pancreatic cancer results.
AACR 2026: Myocarditis Risk, KRAS Inhibitors, mRNA Advances
AACR 2026 featured key updates in oncology, including advancements in KRAS inhibitors, mRNA therapies, and insights into immunotherapy risks. Data highlighted clinical trial results and preclinical progress from companies like Revolution Medicines, Moderna, and Insilico Medicine.
ACRP 2026: Immunology Clinical Research Trends to Watch
Preview of the ACRP 2026 Annual Meeting, focusing on key immunology sessions, speakers, and emerging trends in clinical research. Gain insights into autoimmune diseases, immuno-oncology, and infectious diseases.
Francis Medical's Vanquish System Performs First Commercial Prostate Ablation Procedure in Midwest
Francis Medical's FDA-cleared Vanquish Water Vapor Ablation System completes first commercial prostate tissue ablation procedure in Midwest region.
Aquestive Therapeutics Faces FDA Deficiencies for Anaphylm Drug Application, Class Action Lawsuit Filed
FDA identifies deficiencies in Aquestive's Anaphylm NDA, blocking approval discussions. Class action lawsuit alleges misleading investor communications.
Efemoral Medical's Bioresorbable Scaffold Achieves 97% Patency Rate in Peripheral Artery Disease Trial
Efemoral Medical reports exceptional 3-year results for its bioresorbable scaffold in femoropopliteal disease, achieving 97% primary patency and record-low stenosis rates.
Kyverna's Miv-cel Shows Breakthrough Results in Stiff Person Syndrome Trial, Potentially First Approved Treatment
Kyverna's miv-cel demonstrates statistically significant improvements in Stiff Person Syndrome patients, potentially becoming the first approved treatment for this rare condition.
InVera Medical Reports 90% Vein Closure Success Rate in 12-Month Chronic Venous Disease Trial
InVera Medical's pilot trial shows 90% vein closure rates and significant quality of life improvements for chronic venous disease patients using its infusion device.
REVA Medical's MOTIV Sirolimus-Eluting Scaffold Shows Superior Results in Critical Limb Ischemia Trial
REVA Medical's MOTIV BTK trial met primary endpoint, showing sirolimus-eluting bioresorbable scaffold superiority in critical limb-threatening ischemia patients.
Ractigen Therapeutics RAG-17 Shows 81% Reduction in ALS Biomarker in Phase I Trial
Ractigen's RAG-17 siRNA therapy demonstrates 81% reduction in neurofilament light chain and clinical stabilization trends in SOD1-ALS patients at AAN 2026.
Mabwell's Nectin-4 ADC Bulumtatug Fuvedotin Shows Promise in Cervical Cancer Case Report Published in NEJM
Mabwell's novel Nectin-4 targeting ADC bulumtatug fuvedotin (9MW2821) demonstrates clinical potential in cervical cancer treatment, according to NEJM case report.
Outlook Therapeutics Completes FDA Dispute Resolution Meeting for LYTENAVA Bevacizumab Biosimilar
Outlook Therapeutics completed Federal Dispute Resolution meeting with FDA for ONS-5010/LYTENAVA bevacizumab-vikg retinal disease treatment regulatory pathway.
Follicular Lymphoma Clinical Trials Surge: 45+ Companies Developing New Treatments in 2026
DelveInsight reports 45+ companies actively developing follicular lymphoma treatments with 50+ pipeline drugs in clinical trials, signaling major advances ahead.
Obsidian Therapeutics OBX-115 Phase 2 Melanoma Data to Be Presented at ASCO 2026
Obsidian Therapeutics will present Phase 2 clinical trial results for OBX-115, an autologous TIL cell therapy for advanced melanoma at ASCO 2026.
IceCure Medical ProSense Revenue Surges 30% in Q1 2026 as Cryoablation Technology Gains Traction
IceCure Medical reports 30%+ revenue growth for ProSense cryoablation systems in Q1 2026, highlighting growing adoption of minimally-invasive tumor treatment.
Nuvalent to Present Pivotal Neladalkib Data from ALKOVE-1 Trial at ASCO 2026 for ALK-Positive Lung Cancer
Nuvalent will present pivotal ALKOVE-1 trial data for neladalkib in TKI pre-treated ALK-positive NSCLC patients at ASCO 2026, plus zidesamtinib ROS1 data.
FDA Approves Merck's IDVYNSO: First Non-INSTI, Tenofovir-Free Two-Drug HIV Treatment
FDA approves Merck's IDVYNSO (doravirine/islatravir), the first non-INSTI, tenofovir-free two-drug HIV regimen showing non-inferior efficacy to BIKTARVY.